Viewing Study NCT04478266


Ignite Creation Date: 2025-12-24 @ 4:02 PM
Ignite Modification Date: 2025-12-27 @ 9:31 PM
Study NCT ID: NCT04478266
Status: TERMINATED
Last Update Posted: 2025-09-11
First Post: 2020-07-10
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
Sponsor: Sanofi
Organization: